What if anticoagulant monitoring is overdue when a repeat is requested?

Stop the repeat from becoming an automatic administrative task

A repeat request arrives for an oral anticoagulant. The monitoring date in the GP record is overdue, a result is missing, or the anticoagulation clinic's advice has not reached the prescriber. The patient may have only a few doses left. An automatic issue could continue treatment without enough information to assess safety. An automatic refusal could interrupt anticoagulation and create a different risk. A competent prescriber needs to review the person, the medicine and the monitoring gap promptly, then decide how to maintain safe care.

CQC's GP anticoagulant guidance says the prescriber is responsible for assuring themselves that a prescription is safe and appropriate. It distinguishes warfarin, which needs INR monitoring and dose advice, from direct oral anticoagulants, which need periodic clinical and laboratory review but not warfarin-style anticoagulant effect monitoring. NHS Specialist Pharmacy Service's current DOAC monitoring guidance was updated in August 2026 and emphasises an individual monitoring plan. This article describes an operational response to overdue information. It does not set a drug dose, INR target or universal supply decision.

Flag the request for clinical review. Record what is overdue, the last known result, the patient's supply position, indication and responsible service. Contact the patient if needed to understand what they have taken, whether they have bleeding or clotting symptoms, whether a test was done elsewhere and whether another clinician changed treatment. If symptoms suggest an emergency, use the appropriate urgent pathway. Do not let the monitoring task sit in a general repeat queue with no named clinician while tablets run out.

This page owns a GP repeat request with a monitoring gap for an existing anticoagulant. The GP test-results backlog draft owns an unreviewed result queue. The GP discharge-medicine reconciliation draft owns a post-discharge list mismatch. The medicine safety alert patient-search draft owns an alert-driven cohort action. Each can intersect with anticoagulation, but this page follows the prescriber through the immediate repeat and monitoring decision.

Identify the medicine and monitoring model

Determine whether the patient takes warfarin or a direct oral anticoagulant, and confirm the active prescription, indication, dose, last supply and any recent specialist changes. Do not assume that all medicines described as “blood thinners” use the same monitoring pathway. Warfarin management involves INR measurements and dose advice. A DOAC does not use routine INR to measure its anticoagulant effect, but still requires reviews of renal function, other relevant laboratory results, adherence, adverse effects and dose suitability. The exact schedule and parameters depend on the medicine and patient.

Check who provides monitoring. CQC describes several warfarin models: a hospital anticoagulation service may give testing and dose advice while the GP practice prescribes; a practice may send samples to a laboratory; or point-of-care testing may be done in the practice or community pharmacy. The practice must understand its local arrangement and what the GP prescriber can see. If a hospital clinic owns dose adjustment, obtain current advice and record it rather than guessing from an old yellow book. If the practice performs the test, check whether a result was generated, reviewed and communicated.

For a DOAC, read the current medicine-specific guidance and the patient plan. The NHS Specialist Pharmacy Service notes that monitoring frequency may need to increase with renal impairment, frailty, age, illness or interacting medicines. An annual date on a generic template may be inappropriate for one person and too frequent for another. Do not turn an example interval from professional guidance into an absolute legal rule. The prescriber should document the individual plan and why it fits current risk.

Find the last trustworthy information

Check the GP record, anticoagulation clinic communications, laboratory results, patient-held monitoring book, hospital letters and community pharmacy messages. Verify dates and whether the result belongs to the current treatment. A result visible in the record may not have been acted on. A patient may report that the test was done at a clinic, but the dose instruction may not have arrived. A recent hospital admission may have changed the anticoagulant or temporarily held it. Do not issue from the repeat list until such conflicts have been assessed.

If the result is missing, chase the provider that performed the test through an approved route and record the response. If the patient missed the test, ask why and arrange a feasible alternative. A person may be housebound, unable to use the booking system or unaware that the interval changed. The response should solve the access problem as well as send another reminder. A booked test is not a completed result. Give the clinical owner a check date and escalation if the result does not return.

Make a patient-specific supply decision

The prescriber must balance risks of continuing without adequate information against risks of interruption. The answer may depend on the indication, last monitoring results, current condition, recent bleeding, kidney or liver function, medicine interactions, supply remaining and available urgent testing. There is no safe universal instruction to issue one week's supply, withhold all repeats or switch medicines. Seek anticoagulation, pharmacy or specialist advice where needed and record it. The patient should know what to take while the issue is resolved, according to the clinician's decision.

If a short interim prescription is considered, the clinician should decide its quantity and conditions. It should have a named follow-up action rather than become a recurring workaround. If the clinician decides not to prescribe, arrange prompt clinical review and a safe alternative plan; do not leave the patient to discover the refusal at the pharmacy. Either decision should be visible in the clinical record and explained to the patient. The receptionist or repeat-prescribing clerk should not be asked to make the clinical judgment.

Check electronic repeat dispensing and prescriptions already sent. A practice may flag a monitoring gap today while an earlier issue remains available at the pharmacy. The prescriber should establish what has been issued or dispensed and coordinate any change through the appropriate route. Do not assume removing a repeat template cancels medicine already supplied. If a dose changes after an INR result or clinical review, communicate the current instruction to the patient and relevant pharmacy, and confirm how old packs or schedules will be managed.

Review current bleeding or clotting concerns

Ask about symptoms that may require urgent clinical assessment, using appropriate professional judgment and current pathways. Do not use this article as a symptom checklist or to give self-treatment advice. The practice should have a route for a patient who reports bleeding, head injury, severe symptoms or suspected clot while monitoring is unresolved. Record the assessment and escalation. A routine monitoring appointment may be too slow for a person with acute symptoms, and a prescription decision alone will not address them.

The patient may also have a new medicine that interacts with warfarin or another anticoagulant, an acute illness affecting kidney function, or a recent procedure that changes the plan. Review the whole current context, not just the monitoring date. NICE's atrial fibrillation guidance recommends reviewing the need for and quality of anticoagulation at least annually for people taking anticoagulants for atrial fibrillation, and more often after clinically relevant changes. That recommendation is specific to its guideline population. Other indications and medicines require their own guidance.

Restore monitoring and close the result loop

Arrange the missing test or review with an appropriate service, taking account of urgency. Record who orders it, who will receive the result, who interprets it, who changes treatment if needed and who tells the patient. A shared-care or external anticoagulation arrangement should not leave these steps implicit. If a clinic gives advice but the GP issues the prescription, the GP prescriber needs enough current information to prescribe safely. CQC's guidance says the practice should make sure monitoring and dose advice are in place and visible in the patient record.

For warfarin, follow the local INR and dose pathway. A trained worker may perform point-of-care testing under protocol, but an appropriately trained prescriber should make recommendations that change dose, as CQC explains. Check the test equipment's maintenance and quality assurance if the practice performs testing. Do not infer a new dose from an INR value in an article or generic software task. The clinical team must use the actual result, patient's target and local service model.

For a DOAC, the review may involve blood count, renal and liver assessment, weight, adherence, adverse effects and dose suitability. The current NHS Specialist Pharmacy Service page recommends calculating creatinine clearance for dosing assessment and warns that estimated glomerular filtration rate can overestimate renal function in this context. It also gives situations for more frequent monitoring. A prescriber or pharmacist should apply the current medicine-specific guidance and the full clinical picture. This article does not supply a calculator or a dosing table.

Once the result arrives, record the decision and the next test or review date. Tell the patient what changed, if anything, and how to obtain the next supply. A result filed as “normal” without a repeat decision or patient communication may leave the same problem in place. The GP test-results owner covers a wider result-reconciliation failure. This case should remain open until the monitoring action and prescription status agree.

Find why monitoring became overdue

Check handovers that create invisible monitoring gaps

A monitoring failure can begin when responsibility changes without a clear record. A patient may have moved from hospital anticoagulation follow-up to GP prescribing, changed practice, entered a care home or started receiving medicines through electronic repeat dispensing. Review the transfer document and ask who accepted each task. If the former clinic stopped sending reminders but the practice did not start its own recall, neither organisation may notice the missing test until the next prescription request. Document the current owner rather than relying on an old service name in the record.

The patient may have a current result in another organisation's system. That is useful only when the prescriber can obtain and interpret the result and any dose advice. A patient-held book or app can support the conversation, but the clinician should verify the source and date for a prescribing decision. If information cannot be confirmed quickly, record what was unavailable and why the interim plan is safe. Arrange a clear follow-up to replace the uncertainty with a verified result.

Check whether access needs contributed. A patient who is housebound may need a different sampling route. A person with a hearing impairment may miss telephone reminders. Someone who has recently changed address may never receive a letter. A missed test is not automatically a refusal. Ask what prevented attendance, offer a feasible method and ensure the result returns to the correct prescriber. If the monitoring pathway cannot provide the required test within a clinically safe period, escalate to the anticoagulation or specialist team rather than repeatedly issuing the same generic reminder.

Finally, look at the electronic prescribing configuration. A repeat template may remain active after a clinical review date passes, while a separate recall task has failed. An eRD batch may have been authorised before the monitoring gap was discovered. The prescriber should assess what has already been issued and what future supplies remain possible. A system change should target the actual failure point, with a test that shows a new overdue result would be seen before another unsafe issue.

Review the recall process after the immediate prescribing risk is controlled. Was a test never booked, missed by the patient, performed but not reported, filed under the wrong clinician, or received without a future recall date? Did the practice rely on an external clinic's appointment list without confirmation? Did a patient register recently with an old repeat and no monitoring plan? Each cause needs a different fix. A reminder letter will not resolve a laboratory interface failure. A dashboard will not help if the clinician has no agreed responsibility to interpret the result.

Check whether the interval in the system still fits the patient. A DOAC recall set annually may not respond to worsening renal function or frailty. A warfarin plan may need a different interval after a dose change or interacting treatment. Keep interval decisions clinical and medicine-specific. If the practice identifies several overdue patients, create a clinically prioritised cohort review rather than processing them alphabetically. Ask a pharmacist or anticoagulation lead to define safe triage and review capacity.

Audit a sample of recent repeats. Was the latest monitoring information available when the prescription was signed? Did the prescriber note any overdue action? Were tests arranged and results acted on? Did the patient receive current dose advice? CQC's GP anticoagulant guidance expects systems of accountability, safe prescribing and audit of clinical decision-making where relevant. A signed prescription is not proof of a safe monitoring system if the same gap recurs each month.

If the gap caused harm or a near miss, use the patient safety and candour assessment routes on the facts. Do not assert that every overdue test is automatically a reportable incident. Preserve the clinical decision and the system-learning record. Speak openly with the patient when care has gone wrong and arrange clinical follow-up. The practice should focus on preventing recurrence without obscuring the immediate prescribing decision.

A practical overdue-monitoring control record

Use these questions to keep the patient and system work connected:

The control record belongs in approved clinical systems for patient-specific details. A governance task can track aggregate overdue counts and process fixes with restricted links. It must not become an open list of patients and anticoagulants. If several organisations share the pathway, agree the handover in writing and verify it in a real case. “The hospital monitors” does not tell the GP prescriber whether the patient was tested or what dose was advised.

Keep Complys within its actual product role

The Complys GP and clinic page describes a compliance layer alongside clinical and patient-record systems. Subject to its actual configuration, a practice could use it to assign anticoagulation-protocol review, record staff competence or audit evidence, and follow corrective actions after a monitoring failure. Patient-specific recall, test results, renal calculations, dosing and prescriptions belong in approved clinical and medicines systems. This draft does not claim that Complys calculates creatinine clearance, checks INR, blocks repeat prescribing or sends patient recalls.

Keep the evidence boundary explicit. A compliance task can state that the repeat-prescribing workflow was audited and an overdue-monitoring control was changed. It should not display an identifiable cohort or lab values to all governance users. Verify product permissions and actual workflow before implementation. A due-date reminder may prompt action, but only a clinician can determine whether the monitoring and supply plan is safe for that person.

CTA: Review how Complys can assign anticoagulation governance audits and corrective actions while patient monitoring and prescribing stay in the GP clinical system. Related tool opportunity: An anticoagulant-monitoring governance audit worksheet with roles, recall method, sample review and action test. Do not create a public dosing or renal calculator without specialist validation. Internal links out: GP test-results backlog; GP discharge-medicine change; incident corrective-action effectiveness. Internal links in proposed: Broad GP CQC guide, GP test-results owner and medicines-governance pages after route review.